On this page · 4 sections→
Where the EU money came from
Funding by EU programme. Amounts are Peptomyc SL's own share of each project, not the project's full budget.
- Horizon Europe€2.5M · 1 project
- Horizon 2020€2.3M · 2 projects
Projects
3 EU-funded projects, newest first. Peptomyc SL led 3 of them as coordinator. Each links to the official record.
- MYCureXCoordinator
FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY
Horizon Europe · 2023–2025 · Project on CORDIS ↗
€2.5Mtheir share - MYCureCoordinator
Innovative cancer therapy through Myc inhibition: taking OMO-103 to market
Horizon 2020 · 2019–2022 · Project on CORDIS ↗
€2.2Mtheir share - PEPTO1Coordinator
Feasibility study of a novel treatment for cancer based on a recombinant peptide therapy
Horizon 2020 · 2016–2016 · Project on CORDIS ↗
€50ktheir share
Fields it works in
Research fields recorded on its Horizon projects.
- cells technologies
- commerce
- economics and business
- gene therapy
- lung cancer
- oncology
- prostate cancer
- proteins
Is this your organisation?
Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.
Claim this profile →Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.